Allogene Therapeutics
ALLO
174 hedge funds and large institutions have $402M invested in Allogene Therapeutics in 2024 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 62 increasing their positions, 42 reducing their positions, and 14 closing their positions.
153% more call options, than puts
Call options by funds: $446K | Put options by funds: $176K
129% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 14
48% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 42
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
12% more funds holding
Funds holding: 156 → 174 (+18)
11.37% more ownership
Funds ownership: 78.61% → 89.98% (+11%)
13% less capital invested
Capital invested by funds: $460M → $402M (-$58.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$11.5M |
| 2 |
PSC
Patient Square Capital
Menlo Park,
California
|
+$3.67M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.05M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$1.98M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.4M |
| 2 |
PA
Perceptive Advisors
New York
|
-$7.63M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
-$4.58M |
| 4 |
Primecap Management
Pasadena,
California
|
-$1.83M |
| 5 |
Morgan Stanley
New York
|
-$1.78M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
Prudential Financial
Newark,
New Jersey
| – | -$601K | -214,495 | Closed |
|
|
AA
177
ALPS Advisors
Denver,
Colorado
| – | -$491K | -175,285 | Closed |
|
|
EGM
178
Engineers Gate Manager
New York
| – | -$134K | -47,773 | Closed |
|
179
AQR Capital Management
Greenwich,
Connecticut
| – | -$94K | -33,589 | Closed |
|
|
CIC
180
Cornercap Investment Counsel
Atlanta,
Georgia
| – | -$79.9K | -28,533 | Closed |
|
|
PAG
181
Private Advisor Group
Morristown,
New Jersey
| – | -$33.8K | -12,087 | Closed |
|
182
Amundi
Paris,
France
| – | -$21.9K | -8,011 | Closed |
|
|
NC
183
nVerses Capital
Wellington,
Florida
| – | -$8.68K | -3,100 | Closed |
|
184
Comerica Bank
Dallas,
Texas
| – | -$5.37K | -1,916 | Closed |
|
185
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$777 | -315 | -82% |
|
|
CPA
186
Capital Performance Advisors
Walnut Creek,
California
| – | -$115 | -41 | Closed |
|
|
C
187
Covestor
London,
United Kingdom
| – | +$49 | +20 | +111% |
|
ALLO Hedge Fund Activity: Q4 2024 in Review
174 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q4 2024, worth a combined $402M — down 13% from $460M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new ALLO positions and 14 closed out — a net gain of 18 holders — while 62 added to existing stakes and 42 trimmed.
The largest buyer was Lynx1 Capital Management, adding an estimated $11.5M. The largest seller was Fidelity Investments, cutting an estimated $15.4M.
- 174 institutional investors held Allogene Therapeutics (ALLO) as of Q4 2024, up from 156 in Q3 2024.
- Funds reported $402M of Allogene Therapeutics stock for Q4 2024, down 13% quarter-over-quarter.
- 32 funds opened new Allogene Therapeutics positions in Q4 2024 and 14 closed out, a net change of +18 holders.
- The largest Allogene Therapeutics buyer in Q4 2024 was Lynx1 Capital Management, an estimated $11.5M added.
- The largest Allogene Therapeutics seller in Q4 2024 was Fidelity Investments, an estimated $15.4M sold.
Based on aggregated 13F filings for Q4 2024.